Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations

Long-acting (LA) anti-HIV regimens show promise for increasing dosing intervals and consequently, improving the patients’ quality of life. The first FDA-approved LA therapy is Cabenuva, which comprises rilpivirine (a non-nucleoside reverse transcriptase inhibitor) and cabotegravir (integrase strand...

Descripción completa

Detalles Bibliográficos
Autores principales: Cilento, Maria E., Ong, Yee Tsuey, Tedbury, Philip R., Sarafianos, Stefan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229705/
https://www.ncbi.nlm.nih.gov/pubmed/35746673
http://dx.doi.org/10.3390/v14061202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229705/
https://www.ncbi.nlm.nih.gov/pubmed/35746673
http://dx.doi.org/10.3390/v14061202

Ejemplares similares